Literature DB >> 1413845

Survival rates and prognostic factors in adrenocortical carcinoma.

P Icard1, A Louvel, Y Chapuis.   

Abstract

In the last 12 years, 41 patients with adrenocortical carcinoma were operated on at Cochin Hospital. There were 29 females and 12 males having an average age of 42 +/- 17 years. Seven of them underwent repeat operation for local recurrence after an average interval of 22 months. Eighty per cent of the tumors had secretory activity while 20% did not. Adrenalectomy and lymphadenectomy were performed on all patients. Thirteen (32%) patients underwent extensive resection because of invasive cancer. The same procedure was performed on 7 patients undergoing re-operation. Operative mortality was 4% (2 of 48 patients). Twenty-four patients died of cancer with an average survival time of 22 months (range 2-86 months) and 15 (37%) patients were still alive, 4 of them with metastases, with an average survival time of 51 months. Curative resection for the 31 patients with local (n = 21) or regional disease (n = 10) allowed a 5 year actuarial survival rate of 45%. The 5 year actuarial survival rate for patients undergoing repeat surgery was 33%. Only 1 of the 10 patients with metastases, and who had an impressive response to OP'DDD, was alive 2 years after the operation. The other 9 patients died within 3-4 months after operation. We found that neither patient characteristics or tumor characteristics were of significant prognostic value. There was no overall prolongation of survival in patients receiving OP'DDD. However 4 patients with metastases occurring in the course of their disease experienced an impressive response with OP'DDD and a relatively long survival.

Entities:  

Mesh:

Year:  1992        PMID: 1413845     DOI: 10.1007/bf02067377

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  26 in total

1.  Adrenal cortical carcinoma. A study of 32 patients.

Authors:  R A Hajjar; R C Hickey; N A Samaan
Journal:  Cancer       Date:  1975-02       Impact factor: 6.860

2.  The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring.

Authors:  H van Slooten; A J Moolenaar; A P van Seters; D Smeenk
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01

3.  Adrenal cortical carcinoma: a presentation of 22 cases and a review of the literature.

Authors:  P H Greenberg; C Marks
Journal:  Am Surg       Date:  1978-02       Impact factor: 0.688

4.  [Regression under the influence of OP'DDD of a malignant cortico-adrenaloma and of its metastases (author's transl)].

Authors:  B Charbonnel; J Guillon; M Chupin
Journal:  Nouv Presse Med       Date:  1980-01-19

5.  Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data.

Authors:  A J Hough; J W Hollifield; D L Page; W H Hartmann
Journal:  Am J Clin Pathol       Date:  1979-09       Impact factor: 2.493

6.  Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases.

Authors:  D R King; E E Lack
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

7.  Adrenocortical carcinoma.

Authors:  K Cohn; L Gottesman; M Brennan
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

8.  Flow cytometric analysis of adrenal cortical tumor DNA. Relationship between cellular DNA and histopathologic classification.

Authors:  L S Bowlby; L E DeBault; S R Abraham
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860

9.  Adrenal cortical carcinoma--a continuing challenge.

Authors:  D J Henley; J A van Heerden; C S Grant; J A Carney; P C Carpenter
Journal:  Surgery       Date:  1983-12       Impact factor: 3.982

10.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

View more
  16 in total

1.  Successful removal of large adrenal pheochromocytoma on the right side with liver mobilization.

Authors:  N Aoyama; I Sasagawa; Y Iijima; H Suzuki; Y Kubota; T Nakada
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

2.  Surgical approach to a large left adrenocortical mass with associated tumour thrombosis of the left renal vein: preservation of the ipsilateral kidney.

Authors:  Manuel Pérez Utrilla; Carlos Nuñez Mora; Alejandro Rojo Sebastián; Pedro M Cabrera Castillo; José M García Mediero
Journal:  Adv Urol       Date:  2009-12-13

3.  Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

4.  Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?

Authors:  F Porpiglia; C Fiori; F C Daffara; B Zaggia; A Ardito; R M Scarpa; M Papotti; A Berruti; G V Scagliotti; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-12-22       Impact factor: 4.256

Review 5.  [Recurrent operations on the adrenal glands].

Authors:  M Brauckhoff; H Dralle
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

6.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 7.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 8.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

9.  Spontaneous rupture of a functioning adrenocortical carcinoma.

Authors:  Jin Ook Chung; Dong Hyeok Cho; Jae Hyuk Lee; Dong Deuk Kwon; Dong Jin Chung; Min Young Chung
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

10.  Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed I Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2016-04       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.